Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 21/1/2020
SIETES contiene 92882 citas

 
 
 1 a 20 de 3210 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Robblee JV, Butterfield RJ, Kang AM, Smith JM. Triptan and ergotamine overdoses in the United States. Analysis of the National Poison Data System. Neurology 2020:1. [Ref.ID 103505]
2. Cita con resumen
Hermida RC, Crespo JJ, Domínguez-Sardina M, et al.. Bedtime hypertension treatment improves cardiovascular risk reduction: the Hygia Chronotherapy Trial. Eur Heart J 2019:septiembre. [Ref.ID 103201]
3. Cita con resumen
Mamdani M, Gomes T, Greaves S, Manji S, Juurlink DN, Tadrous M, Kennedy SH, Antoniou T. Association Between Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Blockers, and Suicide. JAMA Network Open 2019;2:e1913304. [Ref.ID 103200]
4.Enlace a cita original Cita con resumen
Suchard MA, Schuemie MJ, Krumholz HM, You SC, Chen RJ, Pratt N, Reich CG, Duke J, Madigan D, Hripcsak G, Ryan PB. Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis. Lancet 2019;394:24 de octubre. [Ref.ID 103199]
5.Enlace a cita original Cita con resumen
Anderson TS, Jing B, Auerbach A, Wray CM, Lee S, Boscardin WJ, Fung K, Ngo S, Silvestrini M, Steinman MA. Clinical outcomes after intensifying antihypertensive medication regimens among older adults at hospital discharge. JAMA Intern Med 2019:19 de agosto. [Ref.ID 103182]
6.Enlace a cita original Cita con resumen
Anónimo. FDA approves new treatment for hypoactive sexual desire disorder in premenopausal women. U.S. Food and Drug Administration 2019:21 de junio. [Ref.ID 103134]
7.Enlace a cita original Cita con resumen
Kim J, Farchione T, Potter A, Chen Q, Temple R. Esketamine for treatment-resistant depression — First FDA-approved antidepressant in a new class. N Engl J Med 2019;381:4 de julio. [Ref.ID 103124]
8.Enlace a cita original Cita con resumen
Desai RJ, Sarpatwari A, Dejene S, Khan NF, Lii J, Rogers JR, Dutcher SK, Raofi S, Bohn J, Connolly JG, Fischer MA, Kesselheim AS, Gagne JJ. Comparative effectiveness of generic and brand-name medication use: A database study of US health insurance claims. PLOS Medicine 2019:13 de marzo. [Ref.ID 103076]
9. Cita con resumen
Brownlee S, Garber J. Overprescribed: High cost isn’t America’s only drug problem. STAT Daily Recap 2019:2 de abril. [Ref.ID 103070]
10. Cita con resumen
Bosco A, López R, Barateau L, Chenini S, Pesenti C, Pépin J-L, Jaussent I, Dauvilliers Y. Effect of psychostimulants on blood pressure profile and endothelial function in narcolepsy. Neurology 2018;90:6 de febrero. [Ref.ID 102916]
11.Enlace a cita original Cita con resumen
Hicks BM, Filion KB, Yin H, Sakr L, Udell JA, Azoulay L. Angiotensin converting enzyme inhibitors and risk of lung cancer: population based cohort study. BMJ 2018;363:24 de octubre. [Ref.ID 102866]
12. Cita con resumen
Sheppard JP, Stevens S, Stevens R, Martin U, Mant J, Richard Hobbs FD, McManus RJ. Benefits and harms of antihypertensive treatment in low-risk patients with mild hypertension. JAMA Intern Med 2018:29 de octubre. [Ref.ID 102837]
14. Cita con resumen
AEMPS. Retirada del mercado de algunos lotes de medicamentos que contienen valsartán. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) 2018:5 de julio. [Ref.ID 102709]
15.Enlace a cita originalTiene citas relacionadas Cita con resumen
Kandzari DE, Böhm M, Mahfoud F, Townsend RR, Weber MA, Pocock S, Tsioufis K, Tousoulis D, Choi JW, East C, Brar S, Cohen SA, Fahy M, Pilcher G, Kario K, on behalf of the show SPYRAL HTN-ON MED Trial Investigators. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet 2018;391:9 de junio. [Ref.ID 102692]
16.Enlace a cita originalTiene citas relacionadas Cita con resumen
Azizi M, Schmieder RE, Mahfoud F, Weber MA, Daemen J, Davies J, Basile J, Kirtane AJ, Wang Y, Lobo MD, Saxena M, Feyz L, Rader F, Lurz P, Sayer J, Sapoval M, Levy T, Sanghvi K, Abraham J, Sharp ASP, Fisher NDL, Bloch MJ, Reeve-Stoffer H, Coleman L, Mullin C, Mauri L, on behalf of the RADIANCE-HTN Investigators. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. Lancet 2018;391:2335-45. [Ref.ID 102691]
17.Enlace a cita originalTiene citas relacionadas Cita con resumen
Blankestijn PJ, Bots ML. Renal denervation in uncontrolled hypertension: the story continues to unfold. Lancet 2018;391:9 de junio. [Ref.ID 102690]
18. Cita con resumen
Dimmitt S, Stampfer H, Martin JH. When less is more – Efficacy with less toxicity at the ED50. Br J Clin Pharmacol 2017;83:1365-8. [Ref.ID 101984]
19. Cita con resumen
Rosich Martí I, Allepuz A, Rodríguez Palomar G, Ortin Font F, Soler Cera M. Impact of an intervention on the prescription of aliskiren after new evidence on safety reported. Pharmacoepidemiol Drug Saf 2017;26:91-6. [Ref.ID 101949]
20. Cita con resumen
Duan L, Ng A, Chen W, Spencer HT, Nguyen J, Shen AY-J, Lee M-S. ß-blocker exposure in pregnancy and risk of fetal cardiac anomalies. JAMA Intern Med 2017;177:885-7. [Ref.ID 101621]
Seleccionar todas
 
 1 a 20 de 3210 siguiente >>